Medical and Noninvasive Therapy for Meniere's Disease

Otolaryngologic Clinics of North America

Volumn 43, Issue 5, 2010, Pages 1081-1090

  Greenberg, Simon L ^a   Nedzelski, Julian M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gentamicin; Medical Management; Meniere's; Steroid; Streptomycin

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOGLYCOSIDE DERIVATIVE; BETAHISTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; DROPERIDOL PLUS FENTANYL; FUROSEMIDE; GENTAMICIN; GLYCEROL; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN; ISOSORBIDE; LITHIUM; PLACEBO; SPIRONOLACTONE; STREPTOMYCIN; UREA;

HEARING AID; HEARING LOSS; HUMAN; HYPERBARIC OXYGEN; LIFESTYLE MODIFICATION; MEDICAL INSTRUMENTATION; MENIERE DISEASE; MENIETT DEVICE; NON INVASIVE PROCEDURE; PATIENT EDUCATION; REVIEW; SODIUM RESTRICTION; STRESS; TINNITUS;

ADRENAL CORTEX HORMONES; AMINOGLYCOSIDES; BETAHISTINE; DIET, SODIUM-RESTRICTED; DIURETICS; HEARING AIDS; HISTAMINE AGONISTS; HUMANS; LIFE STYLE; MENIERE DISEASE; OTOLARYNGOLOGY; PATIENT EDUCATION AS TOPIC; STRESS, PSYCHOLOGICAL; TINNITUS;

EID: 77955722374     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2010.05.005     Document Type: Review

References (59)

1. Kramer G. Traite des maladies de l'oreille (translated by P Meniere) 1848, Bailliere, Paris.
2. Torok N. Old and new in Meniere disease. Laryngoscope 1977, 87:1870-1877.
3. Coelho D.H., Lalwani A.K. Medical management of Menieres disease. Laryngoscope 2008, 118:1099-1108.
4. Thai-Van H., Bounaix M.J., Fraysse B. Menière's disease: pathophysiology and treatment. Drugs 2001, 61:1089-1102.
5. Furstenberg A.C., Lashmet F.H., Lathrop F.D. Menieres symptom complex: medical treatment. Ann Otol Rhinol Laryngol 1934, 43:1035-1047.
6. Thirlwall A., Kundu S. Diuretics for Ménière's disease or syndrome. Cochrane Database Syst Rev 2006, 3. CD00359910. DOI:1002/14651858.CD003599.pub2.
7. Dziadziola J.K., Laurikainen E.L., Rachel J.D., et al. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999, 120:400-405.
8. Botta L., Mira E., Valli S., et al. Effects of betahistine on vestibular receptors of the frog. Acta Otolaryngol 1998, 118:519-523.
9. Botta L., Mira E., Valli S., et al. Effects of betahistine metabolites on frog ampullar receptors. Acta Otolaryngol 2000, 120:25-27.
10. Arrang J.M., Garbarg M., Quach T.T., et al. Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 1985, 111:73-84.
11. Frew I.J.C., Menon G.N. Betahistine hydrochloride in Menieres disease. Postgrad Med J 1976, 52:501-503.
12. Wilmot T.J., Menon G.N. Betahistine in Menieres disease. J Laryngol Otol 1976, 90:833-840.
13. Mira E., Guidetti G., Ghilardi L., et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol 2003, 260:73-77.
14. Schmidt J.T., Huizing E.H. The clinical drug trial in Menieres disease with emphasis on the effect of betahistine SR. Acta Otolaryngol Suppl 1992, 497:1-189.
15. James A., Burton M.J. Betahistine for Menieres disease or syndrome. Cochrane Database Syst Rev 2001, 1. CD001873. DOI:10.1002/14651858.CD001873.
16. Pondugula S.R., Sanneman J.D., Wangemann P., et al. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. Am J Physiol Renal Physiol 2004, 286(6):F1127-F1135.
17. Trune D.R., Kempton J.B., Kessi M. Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope 2000, 110:1902-1906.
18. Itoh A., Sakata E. Treatment of vestibular disorders. Acta Otolaryngol Suppl 1991, 481:617-623.
19. Shea J.J., Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Menieres disease. Otolaryngol Clin North Am 1996, 29:353-359.
20. Silverstein H., Isaacson J.E., Olds M.J., et al. Dexamethasone inner ear perfusion for the treatment of Menieres disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998, 19:196-201.
21. Garduno-Anaya M.A., De Toledo H.C., Hinojosa-Gonzalez R., et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Menieres disease: a two year prospective placebo controlled, double blind, randomized trial. Otolaryngol Head Neck Surg 2005, 133:285-294.
22. Boleas-Aguirre M.S., Lin F.R., Della Santina C.C., et al. Longitudinal results with intratympanic dexamethasone in the treatment of Meniere's disease. Otol Neurotol 2008, 29(1):33-38.
23. Andrews J.C., Ator G.A., Honrubia V. The exacerbation of symptoms in Meniere's disease during the premenstrual period. Arch Otolaryngol Head Neck Surg 1992, 118:74-78.
24. Price T.M., Allen T.C., Bowyer D.L., et al. Ablation of luteal phase symptoms of Menieres disease with leuprolide. Arch Otolaryngol Head Neck Surg 1994, 120:209-211.
25. Gates G.A. Innovar treatment for Meniere's disease. Acta Otolaryngol 1999, 119(2):189-193.
26. Fattori B., De Iaco G., Vannucci G., et al. Alternobaric and hyperbaric oxygen therapy in the immediate and long term treatment of Menieres disease. Audiology 1996, 35:322-334.
27. Yardley L., Kirby S. Evaluation of booklet-based self-management of symptoms in Meniere disease: a randomized controlled trial. Psychosom Med 2006, 68:762-769.
28. Mcneill C., Mcmahon C.M., Newall P., et al. Hearing aids for Meniere's syndrome: implications of hearing fluctuation. J Am Acad Audiol 2008, 19:430-434.
29. Gates G.A., Verrall A., Green J.D., et al. Meniett clinical trial: long-term follow-up. Arch Otolaryngol Head Neck Surg 2006, 132:1311-1316.
30. Mattox D.E., Reichert M. Meniett device for Menieres disease: use and compliance at 3 to 5 years. Otol Neurotol 2007, 29:29-32.
31. Dornhoffer J.L., King D. The effect of the Meniett device in patients with Menieres disease: long-term results. Otol Neurotol 2008, 28:868-874.
32. Rajan G.P., Din S., Atlas M.D. Longterm effects of the Meniett device in Menieres disease: the Western Australian experience. J Laryngol Otol 2005, 119:391-395.
33. Thomsen J., Sass K., Odkvist L., et al. Local overpressure treatment reduces vestibular symptoms in patients with Menieres disease: a clinical, randomized, multicenter, double-blind placebo-controlled study. Otol Neurotol 2005, 26:68-73.
34. Ohmori H. Mechano-electrical transduction currents in isolated vestibular hair cells of the chick. J Physiol 1985, 359:189-217.
35. Waguespack J., Ricci A. Aminoglycoside ototoxicity: permeant drugs cause permanent hair cell loss. J Physiol 2005, 567:359-360.
36. Williams S., Zenner H., Schacht J. Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. Hear Res 1987, 30:11-18.
37. Sha S.H., Qiu J.H., Schacht J. Aspirin to prevent gentamicin induced hearing loss. N Engl J Med 2006, 354:1856-1857.
38. Hoffmann K.K., Silverstein H. Inner ear perfusion: indications and applications. Curr Opin Otolaryngol Head Neck Surg 2003, 11(5):334-339.
39. Shea J.J. Perfusion of the inner ear with streptomycin. Am J Otol 1989, 10:150-155.
40. Shea J.J., Norris C.H. Streptomycin perfusion of the labyrinth. Menieres disease. Proceedings of the Second International Symposium on Menieres disease, June 20-22, 1988 1989, Kugler and Khedini Publ, Cambridge (MA). J.B. Nadol (Ed.).
41. Fowler E.P. Streptomycin treatment for vertigo. Trans Am Acad Ophthalmol Otolaryngol 1948, 52:293-301.
42. Wilson R.W., Schuknecht H.F. Update on the use of streptomycin therapy for Menieres disease. Am J Otol 1980, 2:108-111.
43. Schuknecht H.F. Ablation therapy for the relief of Menieres disease. Laryngoscope 1956, 66:859-870.
44. Khetarpal U., Schuknecht H.F. Temporal bone findings in a case of bilateral Menieres disease treated by parenteral streptomycin and endolymphatic shunt. Laryngoscope 1990, 100:407-414.
45. Silverstein H. Streptomycin treatment for Menieres disease. Ann Otol Rhinol Laryngol Suppl 1984, 112:44-48.
46. Graham M.D., Sataloff R.T., Kemink J.L. Titration streptomycin therapy for bilateral Menieres disease: a preliminary report. Otolaryngol Head Neck Surg 1984, 92:440-447.
47. Larouere M.J., Zappia J.J., Graham M.D. Titration streptomycin therapy in Menieres disease: current concepts. Am J Otol 1993, 14(5):474-477.
48. Langman A.W., Kemink J.L., Graham M.D. Titration streptomycin therapy for bilateral Menieres disease: follow up report. Ann Otol Rhinol Laryngol 1990, 99:923-926.
49. Schuknecht H. Ablation therapy in the management of Menieres disease. Acta Otolaryngol Suppl 1957, 132:1-42.
50. Commins D.J., Nedzelski J.M. Topical drugs in the treatment of Menieres disease. Curr Opin Otolaryngol Head Neck Surg 1996, 4:319-323.
51. Subcommittee on Equilibrium Menieres disease: criteria for diagnosis and evaluation of therapy for reporting. AAO-HNS Bull 1985, 7:6-7.
52. Committee on Hearing and Equilibrium Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menieres Disease. Otolaryngol Head Neck Surg 1995, 113:181-185.
53. Kaasinen S., Pyykko I., Ishizaki H., et al. Intratympanic gentamicin in Menieres disease. Acta Otolaryngol (Stockh) Suppl 1998, 118:294-298.
54. Harner S.G., Driscoll C.L., Facer W., et al. Long-term follow-up of transtympanic gentamicin for Menieres syndrome. Otol Neurotol 2001, 22:210-214.
55. Perez N., Martin E., Garcia-Tapia R. Intratympanic gentamicin for intractable Menieres disease. Laryngoscope 2003, 113:456-464.
56. Wu I.C., Minor L.B. Longterm hearing outcome in patients receiving intratympanic gentamicin for Menieres disease. Laryngoscope 2003, 113:815-820.
57. Cohen-Kerem R., Kisilevsky V., Einarson T.R., et al. Intratympanic gentamicin for Menieres disease: a meta-analysis. Laryngoscope 2004, 114:2085-2091.
58. Nedzelski J.M., Schessel D., Bryce G., et al. Chemical labyrinthectomy: local application for the treatment of unilateral Menieres disease. Am J Otol 1992, 13:18-22.
59. Bodmer D., Morong S., Stewart C., et al. Long-term vertigo control in patients after intratympanic gentamicin instillation for Menieres Disease. Otol Neurotol 2007, 28:1140-1144.